Arrowhead Research said this week that it has signed a deal under which an undisclosed Merck subsidiary will evaluate a novel therapeutic monoclonal antibody candidate developed through its human-derived peptide targeting and discovery program.

RXi also broke out its financial results for 2010 in the filing, reporting a drop in its net loss amid lower research and development spending. The company said, however, that it anticipates its expenses to increase going forward on NeuVax-related expenses.